ArticleClinical & translational immunology2020
Human CLEC9A antibodies deliver Wilms' tumor 1 (WT1) antigen to CD141
Article in Clinical & translational immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- Exploring Clec9a in dendritic cell-based tumor immunotherapy for molecular insights and therapeutic potentials.NPJ vaccines · 2025Review
- Wilms' tumor 1 -targeting cancer vaccine: Recent advancements and future perspectives.Human vaccines & immunotherapeutics · 2024Review
- Engineered Cancer Nanovaccines: A New Frontier in Cancer Therapy.Nano-micro letters · 2024Review
- Review
- Controlling Antigen Fate in Therapeutic Cancer Vaccines by Targeting Dendritic Cell Receptors.Molecular pharmaceutics · 2023Review
- Enhancing the immunogenicity of cancer vaccines by harnessing CLEC9A.Human vaccines & immunotherapeutics · 2022Article
- Antigen targeting to dendritic cells: Still a place in future immunotherapy?European journal of immunology · 2022Review
- Incorporation of Toll-Like Receptor Ligands and Inflammasome Stimuli in GM3 Liposomes to Induce Dendritic Cell Maturation and T Cell Responses.Frontiers in immunology · 2022Article
- Discordance in STING-Induced Activation and Cell Death Between Mouse and Human Dendritic Cell Populations.Frontiers in immunology · 2022Article
- An adjuvant-containing cDC1-targeted recombinant fusion vaccine conveys strong protection against murine melanoma growth and metastasis.Oncoimmunology · 2022Article
- Strategies to overcome DC dysregulation in the tumor microenvironment.Frontiers in immunology · 2022Review
- GM-CSF, Flt3-L and IL-4 affect viability and function of conventional dendritic cell types 1 and 2.Frontiers in immunology · 2022Article
- Expression of clec9a in the oral cancer microenvironment. A preliminary immunohistochemical pilot study.Medicina oral, patologia oral y cirugia bucal · 2021Article
- Mimicking Pathogens to Augment the Potency of Liposomal Cancer Vaccines.Pharmaceutics · 2021Review
- Review
- Vaccines for immunoprevention of cancer.The Journal of clinical investigation · 2021Review
- Type 1 conventional dendritic cells and interferons are required for spontaneous CD4Clinical & translational immunology · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 6 institutions in 4 countries.
Funding
Abstract
objectivesVaccines that prime Wilms' tumor 1 (WT1)-specific CD8
methodsWT1 was genetically fused to antibodies specific for human CLEC9A, DEC-205 or β-galactosidase (untargeted control). Activation of WT1-specific CD8
resultsThe CLEC9A-WT1 vaccine promoted cross-presentation of WT1 epitopes to CD8
conclusionsDelivery of WT1 to CD141
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.